(Q39732691)

14 September 2017

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies (English)

1 reference

relapsing-remitting multiple sclerosis

14 September 2017

0 references

0 references

10

Giancarlo Comi

1 reference

14 September 2017

2

Angelo Ghezzi

1 reference

14 September 2017

7

Lucia Moiola

1 reference

14 September 2017

6

Giorgio Minonzio

1 reference

14 September 2017

4

Bruno Colombo

1 reference

14 September 2017

5

Vittorio Martinelli

1 reference

14 September 2017

8

Mariaemma Rodegher

1 reference

14 September 2017

9

Mauro Zaffaroni

1 reference

14 September 2017

1

Damiano Baroncini

1 reference

14 September 2017

3

Pietro O Annovazzi

1 reference

14 September 2017

26 May 2016

1 reference

Multiple Sclerosis Journal

14 September 2017

1 reference

14 September 2017

22

1 reference

14 September 2017

10

1 reference

14 September 2017

1315-1326

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

14 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Comparative efficacy of switching to natalizumab in active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Sudden unexpected death on fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516650736

21 January 2018

Identifiers

DOI

10.1177/1352458516650736

1 reference

14 September 2017

1 reference

PubMed ID

27230789